TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT04613102

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

Cause of deathRegulatory or ethics Automatic label, confidence 0.9, unverified. How labels are made.
“The study protocol should to be updated (major updates), following the second Health Canada review /requests. The study has been withdrawn form the REB review and will not be performed at SickKids.”

The sponsor’s own words in the registry.

Life of this trial

202020212022Planned start2020-08-01 (planned)Registered2020-10-27Withdrawn (as of)2021-06-18

Vital statistics

Status
Withdrawn
Phase
Phase 2, Phase 3
Sponsor
Elena Pope
Sponsor type
University, hospital or other
Conditions
Epidermolysis Bullosa; Pain; Itch
Interventions
AVCN583601 (3% Cannabidiol cream)
Participants
0
Sites
1
Countries
Canada

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.